Stay updated on Pembrolizumab After Chemotherapy/Proton Reirradiation Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab After Chemotherapy/Proton Reirradiation Clinical Trial page.

Latest updates to the Pembrolizumab After Chemotherapy/Proton Reirradiation Clinical Trial page
- CheckyesterdayChange DetectedThe new screenshot shows only minor visual/layout adjustments with no changes to core study details such as eligibility criteria, interventions, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check29 days agoChange Detected- The page now includes a notice about potential government funding lapse and current operating status, plus a link to the NIH Clinical Center and opm.gov for updates. - The version is updated from v3.1.0 to v3.2.0.SummaryDifference4%

- Check37 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision was updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.3%

- Check58 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%

- Check65 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while several key medical topics and terms related to pembrolizumab and lung cancer have been removed.SummaryDifference4%

Stay in the know with updates to Pembrolizumab After Chemotherapy/Proton Reirradiation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab After Chemotherapy/Proton Reirradiation Clinical Trial page.